Spotlights

Euroclear AUXESIS PHARMA HOLDING AB (publ) has now entered into an agreement with the issuance institute Avanza Sweden. All shareholders will be registered with Euroclear

Valuation AUXESIS 03/2023 Scenario valuation of the shares in AUXESIS PHARMA HOLDING AB (publ) prior to the launch of the company’s analgesic product ASA.P® is

Investor Invitation We are excited to invite you to our first Investor Forum monday the 30th of january at the Karolinska Institute, Huddinge, Sweden. On

News Euroclear Sweden AUXESIS PHARMA HOLDING AB (publ) register of shareholders is in process of being digitalised and transferred to the Euroclear system. As a client

Update There is exciting news in Auxesis Pharma. Trademarks, new areas of application, clinical studies and trials, production facilities, to name a few. Complete pdf

Do you want to join the journey? AUXESIS PHARMA HOLDING AB (publ) is increasing its stock with maximum 600.000 shares at a price of SEK 30/share.Duration for purchasing shares is from 10th

AUXESIS PHARMA HOLDING AB (publ) is now registered with the Swedish Companies Registration Office as a Public Limited Company (PLC) with a share capital of SEK 500,000. A

Scenario valuation of the shares in AUXESIS PHARMA HOLDING AB (publ) prior to the launch of the company’s analgesic product ASA.P® is now available. One-Pager

The shareholders in 559195-6486 AUXESIS PHARMA HOLDING AB (publ), is hereby convened to the Annual General Meeting on June 10, 2022 at 15.00 in the conference

Welcome as Board Members – Charlotta Larsson and Rune Nordström. Thank you to all shareholders for a great meeting and big thanks to Lars Larsson